AXL and non-small cell lung carcinoma: We generated HCC827 human NSCLC cells with acquired resistance to erlotinib or osimertinib by treating them for 80 days with 1,000 nM erlotinib or osimertinib, and we examined AXL expression by western blotting to evaluate the potential relation between acquired resistance and AXL upregulation.